000136197 001__ 136197
000136197 005__ 20240719195438.0
000136197 0247_ $$2doi$$a10.3389/fneur.2024.1417831
000136197 0248_ $$2sideral$$a139155
000136197 037__ $$aART-2024-139155
000136197 041__ $$aeng
000136197 100__ $$0(orcid)0000-0001-6370-218X$$aNavarro-Pérez, María Pilar
000136197 245__ $$aLong-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study
000136197 260__ $$c2024
000136197 5060_ $$aAccess copy available to the general public$$fUnrestricted
000136197 5203_ $$aBackground: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profile and efficacy of BoNTA in CM after 5 years of treatment in a real-life setting.
Methods: We performed a retrospective chart review of patients with CM in relation to BoNTA treatment for more than 5 years in 19 Spanish headache clinics. We excluded patients who discontinued treatment due to lack of efficacy or poor tolerability.
Results: 489 patients were included [mean age 49, 82.8% women]. The mean age of onset of migraine was 21.8 years; patients had CM with a mean of 6.4 years (20.8% fulfilled the aura criteria). At baseline, patients reported a mean of 24.7 monthly headache days (MHDs) and 15.7 monthly migraine days (MMDs). In relation to effectiveness, the responder rate was 59.1% and the mean reduction in MMDs was 9.4 days (15.7 to 6.3 days; p < 0.001). The MHDs were also reduced by 14.9 days (24.7 to 9.8 days; p < 0.001). Regarding the side effects, 17.5% experienced neck pain, 17.3% headache, 8.5% eyelid ptosis, 7.5% temporal muscle atrophy and 3.2% trapezius muscle atrophy. Furthermore, after longer-term exposure exceeding 5 years, there were no serious adverse events (AE) or treatment discontinuation because of safety or tolerability issues.
Conclusion: Treatment with BoNTA led to sustained reductions in migraine frequency, even after long-term exposure exceeding 5 years, with no evidence of new safety concerns.
000136197 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000136197 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000136197 700__ $$aGonzález-Quintanilla, Vicente
000136197 700__ $$aMuñoz-Vendrell, Albert
000136197 700__ $$aMadrigal, Elisabet
000136197 700__ $$aAlpuente, Alicia
000136197 700__ $$aLatorre, Germán
000136197 700__ $$aMolina, Francis
000136197 700__ $$aMonzón, María José
000136197 700__ $$aMedrano, Vicente
000136197 700__ $$aGarcía-Azorín, David
000136197 700__ $$aGonzález-Oria, Carmen
000136197 700__ $$aGago-Veiga, Ana
000136197 700__ $$aVelasco, Fernando
000136197 700__ $$aBeltrán, Isabel
000136197 700__ $$aMorollón, Noemí
000136197 700__ $$aViguera, Javier
000136197 700__ $$aCasas-Limón, Javier
000136197 700__ $$aRodríguez-Vico, Jaime
000136197 700__ $$aCuadrado, Elisa
000136197 700__ $$aIrimia, Pablo
000136197 700__ $$aIglesias, Fernando
000136197 700__ $$aGuerrero-Peral, Ángel Luis
000136197 700__ $$aBelvís, Robert
000136197 700__ $$aPozo-Rosich, Patricia
000136197 700__ $$aPascual, Julio
000136197 700__ $$0(orcid)0000-0001-5139-6031$$aSantos-Lasaosa, Sonia$$uUniversidad de Zaragoza
000136197 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000136197 773__ $$g15 (2024), [7 pp.]$$pFront. neurol.$$tFrontiers in Neurology$$x1664-2295
000136197 8564_ $$s295426$$uhttps://zaguan.unizar.es/record/136197/files/texto_completo.pdf$$yVersión publicada
000136197 8564_ $$s2385934$$uhttps://zaguan.unizar.es/record/136197/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000136197 909CO $$ooai:zaguan.unizar.es:136197$$particulos$$pdriver
000136197 951__ $$a2024-07-19-18:29:06
000136197 980__ $$aARTICLE